Vijaya Diagnostic Centre reported robust year-on-year growth in revenue and profit for the quarter ended June 30, 2024. The company also recommended a dividend of Re. 2 per share.
Vijaya Diagnostic Centre Reports Strong Q1 FY25 Performance
Consolidated Revenue: ₹230.98 crore Consolidated Profit (PAT): ₹53.10 crore Reader Takeaway: Strong revenue and profit growth driven by organic and inorganic expansion, with a dividend payout. ## What just happened Vijaya Diagnostic Centre Ltd. announced its financial results for the quarter ended June 30, 2024. Consolidated revenue stood at ₹230.98 crore, a significant year-on-year increase from ₹188.05 crore in the same period last year. Consolidated profit after tax (PAT) also saw substantial growth, reaching ₹53.10 crore, up from ₹38.59 crore in the prior year quarter. The company's Board has recommended a dividend of Re. 2 per equity share for the financial year 2025-26, subject to shareholder approval. The statutory auditors have issued an unmodified review report on the financial results. ## Why this matters The strong top-line and bottom-line growth indicates healthy business expansion. The recommended dividend offers a direct return to shareholders. The acquisition of Medinova Millennium MRI Services LLP via slump sale signifies inorganic growth, with comparative financials restated to reflect the business combination. ## The backstory Vijaya Diagnostic Centre is a leading diagnostic service provider in India. The company has been focusing on both organic expansion and strategic acquisitions to strengthen its market position. The 'Employee Stock Option Plan 2018' has been utilized, with 179,500 ESOPs granted recently. ## What changes now Shareholders will vote on the proposed dividend at the upcoming Annual General Meeting. The integration of Medinova Millennium MRI Services LLP is expected to contribute to future growth. The company's financial reporting has been adjusted due to the acquisition using the pooling of interest method. ## Risks to watch While the audit opinion is unmodified, the auditor's report noted reliance on another auditor for one subsidiary contributing ₹12.81 crore in revenue. This is a watch point for potential dependencies. ## Peer comparison While specific peer data isn't in the filing, Vijaya Diagnostic Centre operates in the highly competitive Indian diagnostic sector, facing competition from national chains and regional players. ## Context metrics (time-bound) - **Consolidated Revenue (Q1 FY25):** ₹230.98 crore (vs. ₹188.05 crore in Q1 FY24) - **Consolidated PAT (Q1 FY25):** ₹53.10 crore (vs. ₹38.59 crore in Q1 FY24) - **Dividend Recommendation:** Re. 2 per share for FY25-26 - **ESOPs Granted:** 179,500 on May 7, 2026 ## What to track next Investors will monitor the shareholder approval of the dividend, the successful integration of the acquired business, and continued revenue and profit growth in subsequent quarters. The performance of the subsidiary audited by another firm will also be a key point to observe.
